Peptide Immunoaffinity Enrichment Coupled with Mass Spectrometry for Peptide and Protein Quantification

Clinics in Laboratory Medicine

Volumn 31, Issue 3, 2011, Pages 385-396

  Whiteaker, Jeffrey R ^a   Paulovich, Amanda G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Immuno mass spectrometry; Immuno SRM; Quantitative proteomics; Selected reaction monitoring; SISCAPA; Stable isotope dilution

Indexed keywords

MONOCLONAL ANTIBODY; PEPTIDE; REAGENT; ANTIBODY; PROTEIN; TRYPSIN;

ACCURACY; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; COST CONTROL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; NONHUMAN; PEPTIDE IMMUNOAFFINITY ENRICHMENT COUPLED WITH MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REACTION OPTIMIZATION; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; CHEMISTRY; IMMUNOLOGY; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PLASMA;

ANTIBODIES; HUMANS; IMMUNOASSAY; ISOTOPE LABELING; LIMIT OF DETECTION; MASS SPECTROMETRY; PEPTIDES; PLASMA; PROTEINS; PROTEOMICS; TRYPSIN;

EID: 85058721573     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.07.004     Document Type: Review

References (57)

1. Want E.J., Cravatt B.F., Siuzdak G. The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem 2005, 6:1941-1951.
2. Chace D.H., Kalas T.A. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005, 38:296-309.
3. Barr J.R., Maggio V.L., Patterson D.G., et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996, 42:1676-1682.
4. Gerber S.A., Rush J., Stemman O., et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 2003, 100:6940-6945.
5. Kuhn E., Wu J., Karl J., et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4:1175-1186.
6. Barnidge D.R., Goodmanson M.K., Klee G.G., et al. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 2004, 3:644-652.
7. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
8. Agger S.A., Marney L.C., Hoofnagle A.N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid chromatography-multiple reaction monitoring/mass spectrometry. Clin Chem 2010, 56:1804-1813.
9. Lange V., Picotti P., Domon B., et al. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
10. Pan S., Aebersold R., Chen R., et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009, 8:787-797.
11. Addona T.A., Abbatiello S.E., Schilling B., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
12. Kuzyk M.A., Smith D., Yang J., et al. MRM-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8:1860-1877.
13. Keshishian H., Addona T., Burgess M., et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6:2212-2229.
14. Zhou Y., Aebersold R., Zhang H. Isolation of N-linked glycopeptides from plasma. Anal Chem 2007, 79:5826-5837.
15. Ackermann B.L., Berna M.J. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007, 4:175-186.
16. Nedelkov D. Mass spectrometry-based immunoassays for the next phase of clinical applications. Expert Rev Proteomics 2006, 3:631-640.
17. Kiernan U.A. Quantitation of target proteins and post-translational modifications in affinity-based proteomics approaches. Expert Rev Proteomics 2007, 4:421-428.
18. Parker C.E., Pearson T.W., Anderson N.L., et al. Mass-spectrometry-based clinical proteomics-a review and prospective. Analyst 2010, 135:1830-1838.
19. Anderson N.L., Anderson N.G., Haines L.R., et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Antipeptide Antibodies (SISCAPA). J Proteome Res 2004, 3:235-244.
20. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347:3-11.
21. Tate J., Ward G. Interferences in immunoassay. Clin Biochem Rev 2004, 25:105-120.
22. Ismail A.A. Interference from endogenous antibodies in automated immunoassays: what laboratorians need to know. J Clin Pathol 2009, 62:673-678.
23. Whiteaker J.R., Zhao L., Anderson L., et al. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010, 9:184-196.
24. Whiteaker J.R., Lin C., Kennedy J., et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011, 29:625-634.
25. Whiteaker J.R., Zhao L., Zhang H.Y., et al. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 2007, 362:44-54.
26. Hoofnagle A.N., Becker J.O., Wener M.H. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008, 54:1796-1804.
27. Kuhn E., Addona T., Keshishian H., et al. Developing multiplexed assays for Troponin I and Interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009, 55:1108-1117.
28. Greenbaum J.A., Andersen P.H., Blythe M., et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 2007, 20:75-82.
29. Blythe M.J., Flower D.R. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 2005, 14:246-248.
30. Whiteaker J.R., Zhao L., Abbatiello S.E., et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 2011, 10. M110.005645.
31. Schoenherr R.M., Zhao L., Whiteaker J.R., et al. Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry. J Immunol Methods 2010, 353:49-61.
32. Pope M.E., Soste M.V., Eyford B.A., et al. Antipeptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique. J Immunol Methods 2009, 341:86-96.
33. Razavi M., Pope M.E., Soste M.V., et al. MALDI immunoscreening (MiSCREEN): a method for selection of antipeptide monoclonal antibodies for use in immunoproteomics. J Immunol Methods 2011, 364:50-64.
34. Poetz O., Hoeppe S., Templin M.F., et al. Proteome wide screening using peptide affinity capture. Proteomics 2009, 9:1518-1523.
35. Planatscher H., Supper J., Poetz O., et al. Optimal selection of epitopes for TXP-immunoaffinity mass spectrometry. Algorithms Mol Biol 2010, 5:28.
36. Hoeppe S., Schreiber T.D., Planatscher H., et al. Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification. Mol Cell Proteomics 2011, 10. M110.002857.
37. Berna M., Schmalz C., Duffin K., et al. Online immunoaffinity liquid chromatography/tandem mass spectrometry determination of a type II collagen peptide biomarker in rat urine: investigation of the impact of collision-induced dissociation fluctuation on peptide quantitation. Anal Biochem 2006, 356:235-243.
38. Li W.W., Nemirovskiy O., Fountain S., et al. Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: a biomarker of matrix metalloproteinase activity and osteoarthritis in human urine. Anal Biochem 2007, 369:41-53.
39. Nemirovskiy O., Li W.W., Szekely-Klepser G. Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis. Methods Mol Biol 2010, 641:253-270.
40. Anderson N.L., Jackson A., Smith D., et al. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009, 8:995-1005.
41. Nelson R.W., Krone J.R., Bieber A.L., et al. Mass spectrometric immunoassay. Anal Chem 1995, 67:1153-1158.
42. Oran P.E., Jarvis J.W., Borges C.R., et al. Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin Appl 2011, [Epub ahead of print].
43. Trenchevska O., Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci 2011, 9:19.
44. Oran P.E., Jarvis J.W., Borges C.R., et al. C-peptide microheterogeneity in type 2 diabetes populations. Proteomics Clin Appl 2010, 4:106-111.
45. Warren E.N., Elms P.J., Parker C.E., et al. Development of a protein chip: a MS-based method for quantitation of protein expression and modification levels using an immunoaffinity approach. Anal Chem 2004, 76:4082-4092.
46. Jiang J., Parker C.E., Hoadley K.A., et al. Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin Appl 2007, 1:1651-1659.
47. Jiang J., Parker C.E., Fuller J.R., et al. An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis. Anal Chim Acta 2007, 605:70-79.
48. Reid J.D., Holmes D.T., Mason D.R., et al. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom 2010, 21:1680-1686.
49. Whiteaker J.R., Zhang H., Zhao L., et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007, 6:3962-3975.
50. Neubert H., Gale J., Muirhead D. Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. Clin Chem 2010, 56:1413-1423.
51. Ahn Y.H., Lee J.Y., Lee J.Y., et al. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009, 8:4216-4224.
52. Hoofnagle A.N., Wener M.H. Serum thyroglobulin: a model of immunoassay imperfection. Clin Lab Int 2006, 12:12-14.
53. Kippen A.D., Cerini F., Vadas L., et al. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type II diabetic individuals with comparison to immunoassay. J Biol Chem 1997, 272:12513-12522.
54. Janecki D.J., Bemis K.G., Tegeler T.J., et al. A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme. Anal Biochem 2007, 369:18-26.
55. Proc J.L., Kuzyk M.A., Hardie D.B., et al. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J Proteome Res 2010, 9:5422-5437.
56. Zhao Y., Widen S.G., Jamaluddin M., et al. Quantification of activated NF-{kappa}B/RelA complexes using ssDNA aptamer affinity - stable isotope dilution-selected reaction monitoring-mass spectrometry. Mol Cell Proteomics 2011, 10. M111.008771.
57. Whiteaker J.R., Zhao L., Lin C., et al. Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry. Mol Cell Proteomics 2011, [Epub ahead of print].